Anupam Rasayan India Ltd
Anupam Rasayan India Q2 FY26: Revenue ₹731.4 Cr
Q2 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #18 of 71 in Chemicals & Petrochemicals
See the sector's top 10 — free with your mobile number.
The short version
The company expects total revenue growth of over 50% in FY26, driven by recovery in agrochemical sales and growth in pharmaceutical and polymer segments (Page 7). The company expects over 50% total revenue growth for FY26, driven by recovery in agrochemical sales and growth in polymer and pharma segments. - EBITDA margins are anticipated to stabilize around 25% (±1%), slightly below earlier guidance of 26-28%, due to some lower-margin revenue in specific segments. - Investment in new plants (Rs.
From Anupam Rasayan India Ltd's Q2 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- The company expects total revenue growth of over 50% in FY26, driven by recovery in agrochemical sales and growth in pharmaceutical and polymer segments (Page 7).
- Revenue from operations in Q2 FY26 was ₹731.4 crores, up 148.8% YoY; H1 FY26 revenue was ₹1,217.2 crores, up 122.1% YoY (Page 6).
- Continued strong growth in export markets, with 58% of total revenue from exports (Page 4).
- The company anticipates further revenue contributions (~₹450 crore) in FY26 from a healthy order book of ₹14,646 crores spread over 5-7 years (Page 4).
2 more points from Anupam Rasayan India Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Anupam Rasayan India Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company has completed a major CapEx of Rs. 678 crore announced in September 2022, fully deployed with new plants now operational and expected to contribute revenue going forward.
- An additional CapEx of approximately Rs. 1,000 crore has been made recently; the investments will start yielding results in the future.
- These investments include a combination of three new plants that were previously under construction.
- Focus remains on growth in pharma, polymer, and performance chemical segments, requiring increased working capital.
2 more points from Anupam Rasayan India Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Anupam Rasayan India Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The order book stands healthy at approximately ₹14,646 crore.
- These orders are spread over a period of 5 to 7 years.
- Significant progress has been made in commercializing the majority of these products during the year.
2 more points from Anupam Rasayan India Ltd's call on order book
Create a free account to keep reading this call
Anupam Rasayan India Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹636 Cr, net profit ₹56 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Anupam Rasayan India Ltd's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Gujarat Alkalies (Q2 FY26)
2,136.64 Crores (Page 21). Key investor presentation takeaways from Gujarat Alkalies & Chemicals Ltd's Q2 FY26 investor presentation — and how it ranks against
- Dynemic Products Ltd (Q2 FY26)
Quarterly revenue for Q2 FY 25-26: ₹8,935 lakhs (Page 12, 10, 5) . Key investor presentation takeaways from Dynemic Products's Q2 FY26 investor presentation — a
- Platinum Industries Ltd (Q2 FY26)
Q2FY26 Revenue from Operations (Consolidated): INR 983.8 Mn, down 1% YoY from INR 996.4 Mn in Q2FY25. Key investor presentation takeaways from Platinum Industri
- IVP Ltd (Q2 FY26)
Revenue from Operations for Q2FY26: ₹146.95 crores . Key investor presentation takeaways from IVP's Q2 FY26 investor presentation — and how it ranks against sec
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Anupam Rasayan India Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Anupam Rasayan India Ltd Q2 FY26 results?
The company expects total revenue growth of over 50% in FY26, driven by recovery in agrochemical sales and growth in pharmaceutical and polymer segments (Page 7). The company expects over 50% total revenue growth for FY26, driven by recovery in agrochemical sales and growth in polymer and pharma segments. - EBITDA margins are anticipated to stabilize around 25% (±1%), slightly below earlier guidance of 26-28%, due to some lower-margin revenue in specific segments. - Investment in new plants (Rs.
What is Anupam Rasayan India Ltd share price analysis?
Anupam Rasayan India Ltd currently shows a neutral. The stock trades at a P/E of 76.6 with a market cap of ₹13,389 Cr. Investors should review the full earnings analysis for detailed insights.
Is Anupam Rasayan India Ltd planning capital expenditure?
The company has completed a major CapEx of Rs.
Keep Anupam Rasayan India Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.